Innate Pharma (IPHA) Net Cash Flow (2019 - 2025)
Innate Pharma's (IPHA) quarterly Net Cash Flow came in at -$6.4 million in Q4 2024, down 203.51% YoY from $6.2 million in Q1 2024, and down 37.78% on a QoQ basis from -$4.7 million in Q2 2024.
Innate Pharma (IPHA) Net Cash Flow (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 6 years of Net Cash Flow data on file, last reported at -$6.4 million in Q4 2024.
- Quarterly Net Cash Flow fell 203.51% year-over-year to -$6.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$11.1 million (up 25.24% YoY) and the FY2025 annual result came in at -$45.9 million, down 1058.61% from the prior year.
- Net Cash Flow declined to -$6.4 million in Q4 2024, from -$4.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of -$1.0 million in Q4 2021 to a low of -$17.3 million in Q4 2020.
- A 5-year average of -$5.3 million and a median of -$2.0 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2021 — Net Cash Flow surged 93.95% — and 2024, when it sank 203.51%.
- Tracing IPHA's Net Cash Flow over 5 years: stood at -$17.3 million in 2020, then surged by 93.95% to -$1.0 million in 2021, then sank by 77.79% to -$1.9 million in 2022, then fell by 13.42% to -$2.1 million in 2023, then slumped by 203.51% to -$6.4 million in 2024.
- The last three Net Cash Flow figures came in at -$6.4 million (Q4 2024), -$4.7 million (Q2 2024), and -$2.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - | -61.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2024 | -6.42 Mn |
| Jun 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | -4.66 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Jun 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | -1.62 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Dec 31, 2021 | -1.05 Mn |
| Dec 31, 2021 | -1.05 Mn |
| Jun 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | -1.77 Mn |
| Dec 31, 2020 | -17.34 Mn |
| Dec 31, 2020 | -17.34 Mn |